Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Osimertinib + SRS for Lung Cancer
Recruiting3 awardsPhase 2
Toronto, Ontario
This trial is testing osimertinib alone and with precise radiation therapy in patients with a specific type of lung cancer that has spread to the brain. Osimertinib blocks a protein that helps cancer grow, while the radiation therapy targets brain tumors with focused radiation.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service